New injectable methotrexate aims to tame rheumatoid arthritis with fewer side effects
NCT ID NCT06565273
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests an injectable form of methotrexate called FBL-MTX for people with moderate-to-severe rheumatoid arthritis. The drug is designed to deliver methotrexate directly into the body using tiny fat bubbles, which may improve how well it works and reduce side effects compared to the standard pill form. The study includes two groups: those who have never taken disease-modifying drugs and those who did not respond well to or could not tolerate oral methotrexate. Researchers will adjust the dose based on each person's response over 14 weeks to find the best balance of benefit and safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
FBL-MTX (folate-based liposomes encapsulating methotrexate)
What this could lead to
If successful, this could offer a more effective and better-tolerated treatment option for people with rheumatoid arthritis who cannot take oral methotrexate.
What could go wrong
This is an early phase 2 study with only 40 participants, so results may not apply to everyone. The drug may still cause side effects or fail to show clear benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Unidade Local de Saúde da Guarda, EPE
Guarda, 6300-858, Portugal
-
Unidade Local de Saúde da Região de Aveiro, EPE
Aveiro, 3814-501, Portugal
-
Unidade Local de Saúde da Região de Leiria, EPE
Leiria, 2410-197, Portugal
-
Unidade Local de Saúde de Braga, EPE, Centro Clínico Académico de Braga (2CA-Braga)
Braga, 4710-243, Portugal
-
Unidade Local de Saúde de Gaia e Espinho, EPE
Vila Nova de Gaia, 4434-502, Portugal
-
Unidade Local de Saúde de São João, EPE
Porto, 4200-319, Portugal
-
Unidade Local de Saúde do Alto Ave, EPE
Guimarães, 4835-044, Portugal
-
Unidade Local de Saúde do Alto Minho, EPE
Ponte de Lima, 4990-041, Portugal